A Study of BBT001
Phase 1
198
about 1.9 years
18–65
1 site in NY
About this study
Researchers are testing a treatment called BBT001 in two groups: healthy volunteers and adults with atopic dermatitis. The trial will last for 709 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BBT001
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of participants with adverse events following single and multiple administration of BBT001
Secondary: Pharmacokinetics parameters- - Elimination Half-life (t1/2)., Pharmacokinetics parameters- Area under the curve (AUC), Pharmacokinetics parameters- Time for maximum observed Concentration (Tmax), Pharmacokinetics parameters- Total clearance (CL), Pharmacokinetics parameters- Volume of distribution (Vz), Pharmacokinetics parameters- maximum observed Concentration (Cmax)
Dermatology